MEDTECH INSIGHT

20 Feb 2018 | Analysis

QUOTED. Feb. 20, 2018. Ricki Chase.

by

Lachman Consultant Services' Ricki Chase sees too many companies falling down on design control activities when they set out to make combination device/drug products. Check out what she said here.

"Design control is going to be required for a combination product. And it's hard to go back and do a retrospective design history file, because you've not captured a lot of the information that you need to do those things, such as design verification and design validation, along the way. And the fact is, if you're not caught [with inadequate design control] on submission of [your US FDA premarket] application, you will be caught at the [FDA] pre-approval inspection when they ask to review your design control, or in post-market, when they come to do a post-market approval inspection, or a routine inspection, and they ask you about your design control." –Ricki Chase, compliance practice director, Lachman Consultant Services

• Find out more: Compliance 360° Part 13: Navigating The Quicksand Of Device/Drug Combo Products (2 of 2)

Click here for a free trial of Medtech Insight